Stock Analysis
GE HealthCare Technologies Inc. Common StockGEHC
P/E 15.83×· 4Y range 12.35–107.85×· 27th percentile of history
Sector: Healthcare · Industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus
AnalystsBuy28 analystsP/E 15.8× sits at the 27th percentile of its 3.7808578599133016-year history.
Cash covers 17% of debt · FY 2022.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality70
Risks
- Growth26
- Financial Health47
Mixed picture — no clear quality or value edge.
Bull Case
- ✓ROE 19.1% — efficient capital deployment
- ✓Interest coverage 10.3× — debt well covered
What's happening with GEHC
Profile
Strong valuation; growth and financial health lag behind.
How is each axis scored?
- Valuation75/100 · Strong
- P/E vs own history (27th pct)20/25
- FCF yield (5.0%)20/25
- P/S (1.5x)25/25
- EV/EBIT (n/a)10/25
- Growth26/100 · Weak
- Revenue CAGR (4.1%)6/25
- Net income CAGR (-1.9%)0/25
- EPS CAGR 5Y (-2.1%)0/25
- Fwd implied growth (26.1%)20/25
- Profitability57/100 · Moderate
- ROIC (10.6%)12/25
- ROE (19.1%)20/25
- Net margin (9.3%)13/25
- Operating margin (12.9%)12/25
- Financial Health47/100 · Weak
- Altman Z (1.84)10/25
- Current ratio (1.37)12/25
- Interest coverage (10.3x)25/25
- Net cash / debt (n/a)0/25
- Quality70/100 · Moderate
- Piotroski F (4/9)10/25
- Beneish M (-2.23)20/25
- FCF conversion (80%)15/25
- Margin stability (σ 1.2%)25/25
- Moat56/100 · Moderate
- ROIC >12% years (1/5 yrs)0/25
- Median gross margin (40.5%)13/25
- FCF-positive years (5/5 yrs)25/25
- Worst-year net margin (worst 8.0%)18/25
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. Show more
The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Headquarters: CHICAGO, IL · Employees: 54,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
75B+P/E (TTM)15.8xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 4Y history: 12.4x–107.8x · 27th pct
P/FCF20.1xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.0%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 4Y history: 0.5%–5.8% · 89th pct
P/S (TTM)1.48xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 4Y history: 1.3x–8.5x · 11th pct
EV/EBITDA13.1xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral — vs own 4Y history: 12.6x–14.9x · 65th pct
EV/Sales1.9xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E12.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.03xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.18C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.20%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio3.2%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
57CROIC10.6%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE19.1%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA5.4%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin9.3%C
Grade C: AverageNet Income / Revenue
Operating Margin12.9%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin39.5%C
Grade C: AverageGross Profit / Revenue
FCF Margin7.4%D
Grade D: LowFCF / Revenue
True FCF Margin6.7%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
26ERevenue CAGR4.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-1.9%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-2.1%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth26.1%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income7.8%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.7%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
47D+Altman Z-Score1.84C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.37xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.93xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage10.3xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.96xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
70B+Piotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.23A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion79.5%C
Grade C: AverageFCF / Net Income
Margin Stability1.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.5%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.58xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Grogan William K Filed | Grogan William K | Grant / award | +31.9K | |
Grogan William K Filed | Grogan William K | Grant / award | +12.8K | |
Grogan William K Filed | Grogan William K | Grant / award | +62.3K | |
Estrampes Catherine Filed | Estrampes Catherine | Tax withholding | -508 | |
Rackliffe Philip Filed | Rackliffe Philip | Tax withholding | -798 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kass-Hout Taha Filed | Kass-Hout Taha | Tax withholding | -1502 | |
Newcomb George A. Filed | Newcomb George A. | Tax withholding | -112 | |
O'Neill Kevin Michael Filed | O'Neill Kevin Michael | Tax withholding | -718 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
56CROIC >12% Years1/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)40.5%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor8.0%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$4.39
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.60
Cash & short-term investments per share (Finnhub)
Book Value / Share$24.30
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$10.00B
Total debt obligations (short + long term)
Cash & Equiv.—
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$10.38B
Shareholders' equity (book value)
Asset / Liability1.40xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$31.42B
Current Market Capitalization
Beta0.84B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: GE HealthCare Technologies Inc. Common Stock (GEHC)
GEHC is down 1.11% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for GE HealthCare Technologies Inc. Common Stock. Altman Z-Score of 1.84 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -2.23 suggests a low likelihood of earnings manipulation.
- At a valuation score of 75/100, GEHC trades near the cheapest end of its own historical range (P/E 15.8).
See how GEHC ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GEHC moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | Regular | 67.56 | +2.77% | 2.04 |
| Oct 12 | After-hours | 68.00 | +3.44% | 2.55 |
| Sep 22 | Pre-market | 65.84 | +1.59% | 2.20 |
| Sep 22 | Regular | 66.36 | +2.39% | 2.95 |
| Sep 22 | After-hours | 66.00 | +1.84% | 2.43 |
Frequently Asked Questions about GEHC
What is the current GE HealthCare Technologies Inc. Common Stock (GEHC) stock price?
GEHC is trading at $69.57 at the last market close, down 1.11% on the session. PreMarketPrice tracks GEHC pre-market, intraday and after-hours prices.
Is GEHC stock a buy right now?
PreMarketPrice's quantitative model rates GE HealthCare Technologies Inc. Common Stock's financial health at 47/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is GEHC stock overvalued?
GE HealthCare Technologies Inc. Common Stock trades at a trailing P/E of 15.8 and our valuation score rates it 75/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does GE HealthCare Technologies Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for GEHC. The Earnings section lists recent reports and updates as dates are announced.
What sector does GE HealthCare Technologies Inc. Common Stock operate in?
GE HealthCare Technologies Inc. Common Stock operates in the Healthcare sector, within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does GE HealthCare Technologies Inc. Common Stock do?
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment.
About GE HealthCare Technologies Inc. Common Stock (GEHC) Stock
GE HealthCare Technologies Inc. Common Stock (GEHC) is a US-listed stock operating in the Healthcare sector, specifically the X-Ray Apparatus & Tubes & Related Irradiation Apparatus industry. As of the latest update, GE HealthCare Technologies Inc. Common Stock is trading at $69.57, down 1.11% on the day with a market capitalization of $31.4 billion. The financial health score for GEHC is 47/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GEHC stock.
GEHC Stock Analysis & Key Metrics
On PreMarketPrice, you can track GE HealthCare Technologies Inc. Common Stock (GEHC) across multiple dimensions:
- Pre-market price & movement: Real-time GEHC stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GEHC with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for GE HealthCare Technologies Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 47/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GEHC.
- Sector peers: Compare GEHC against 4 other healthcare stocks on key financial metrics.
Is GEHC a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate GE HealthCare Technologies Inc. Common Stock (GEHC) as an investment. The financial health score of 47/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.GE HealthCare Technologies Inc. Common Stock (GEHC) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.